18. März 2026

On 16 March 2026, CRISPR Therapeutics AG (NASDAQ: CRSP) successfully issued a USD 600 million aggregate principal amount of convertible senior notes. The convertible senior notes were offered in a private offering to qualified institutional buyers. The convertible senior notes carry a semiannual effective coupon of 1.7308% and will mature on 1 March 2031, unless earlier converted, redeemed or repurchased. Subject to the terms and conditions of the offering, holders of the convertible senior notes may convert all or any portion of their notes into common shares of CRISPR Therapeutics.

CRISPR Therapeutics is a Switzerland-based leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases.

Walder Wyss advised CRISPR Therapeutics on all Swiss legal and tax aspects of this transaction. The Walder Wyss team was led by Alex Nikitine (Partner, Corporate / M&A, Capital Markets) and Iliana Djagova (Partner, Corporate / M&A, Capital Markets) and further included Dimitrios Berger (Managing Associate, Corporate / M&A, Capital Markets) and Kevin Caratsch (Associate, Corporate / M&A, Capital Markets) as well as Maurus Winzap (Partner, Tax) and Vangelis Kalaitzidakis (Managing Associate, Tax).